Genentech keeps up growth, cites broader Avastin use

07/12/2007 | Forbes

Genentech says its best-selling cancer drug continues to push the company's growth and shows future promise. It has begun Phase III testing on Avastin as a treatment for a specific form of lung cancer and as a second-line treatment for colon cancer. The biotech also is talking to the FDA about Avastin as a possible combined therapy for advanced kidney cancer.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA